Stanley Fiel, MD
Pulmonary Disease · Morristown, NJNPI 1497727697
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $59,140 of the $83,907 with a category attached, or 70.5%. Gilead accounts for 74.1% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $35,374 and has fallen 99.4% since, to $212 in 2025. Among pulmonary disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $364.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$62K
- Mylan Specialty L.p.$16K
- Vertex$2K
- AbbVie$2K
- Insmed, Inc.$1K
- Chiesi USA, Inc.$394
- plus $869 from 17 others
Across 35 payments — averaging $33,616 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$1.2M
- AbbVie$11K
- Vivus LLC$1K
What the payments were for
- Consulting fees$6,9908%
- Speaking & faculty fees$59,14070%
- Travel & lodging$12,59115%
- Food & beverage$5,0176%
- Education$920%
- Gifts$760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 77 | $62,177 |
| Mylan Specialty L.p. | 13 | $16,002 |
| Vertex | 22 | $1,762 |
| AbbVie(2 entities) | 41 | $1,655 |
| Insmed, Inc. | 14 | $1,049 |
| Chiesi USA, Inc. | 11 | $394 |
| Pfizer | 10 | $148 |
| Merck | 8 | $134 |
| Aimmune Therapeutics, Inc. | 5 | $100 |
| Baxter Healthcare | 4 | $82 |
| Advanced Respiratory, Inc | 4 | $75 |
| Nestle Healthcare Nutrition Inc. | 4 | $64 |
| Johnson & Johnson | 3 | $44 |
| Dynavax Technologies Corporation | 3 | $39 |
| Abbott | 2 | $29 |
| Avanir Pharmaceuticals, Inc. | 2 | $28 |
| Monaghan Medical Corporation | 1 | $27 |
| Alcresta Therapeutics, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Olympus America Inc. | 1 | $17 |
| Amgen | 1 | $14 |
| Electromed, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cayston$34,938
- Yupelri$5,830
- Veklury$3,150
- TOBI Podhaler$1,590
- Arikayce$148
- BRONCHITOL$135
- PERTZYE$135
- TEFLARO$106
How this compares
$83,907 in reported general payments places this provider in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 115 | $3,154,611 |
| CreonLipase/Protease/Amylase | 12 | $119,336 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 47 | $27,031 |
| Spiriva RespimatTiotropium Bromide | 13 | $13,924 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $13,782 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $11,465 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $7,196 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $4,173 |
| Ventolin HfaAlbuterol Sulfate | 19 | $1,652 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $719 |
| Montelukast Sodium | 19 | $316 |
| Tramadol Hcl | 24 | $154 |
| Azithromycin | 12 | $102 |
| Levofloxacin | 12 | $102 |
| Zolpidem Tartrate | 12 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $1,762 | $3,154,611115 claims |
| AbbVieCreon | $1,655 | $119,33612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Morristown
- Joseph HoffmanPark Ridge$1.1M
- Reynold PanettieriNew Brunswick$1M
- Robert SussmanSummit$551K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
- Richard MillerNewark$328K
- Jason ShatkinParamus$282K
- Anthony RickettiTrenton$225K
- Jeffrey MiskoffManasquan$176K
- Peter SacconeLinwood$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.